Publications
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Practical approach to management of chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab2013 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Therapy of elderly/comorbid patients with chronic lymphocytic leukemia2013 | Faculty of Medicine in Hradec Králové
- Ofatumumab treatment of fludarabine and alemtuzumab refractory patients2012 | Faculty of Medicine in Hradec Králové
- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
Loading network view...